Mitogenic activity of growth factors in the human endometrial adenocarcinoma cell lines HEC-1-A and KLE.
Endometrial adenocarcinoma is the most common gynecologic malignancy occurring in the United States. Evidence is accumulating that links peptide growth factors with malignant proliferation. Epidermal growth factor (EGF) and insulin-like growth factor I (IGF-I) are known mitogens for endometrial adenocarcinoma in vitro. However, the biological activity of other growth factors in this malignancy is unclear. This study was undertaken to determine the influence of growth factors on the mitogenic activity of the human endometrial adenocarcinoma cell lines HEC-1-A and KLE. Incubation with EGF, IGF-I, insulin-like growth factor II (IGF-II), or insulin stimulated a time-dependent mitogenic response in both cell lines, with the peak response occurring at 24 hr for HEC-1-A and 48 hr for KLE. After two doubling intervals, the number of HEC-1-A cells was increased 3.5-fold by EGF (100 ng/ml), 2.7-fold by IGF-I (100 ng/ml), 2.3-fold by IGF-II (100 ng/ml), and 2.2-fold by insulin (1000 ng/ml) when compared to untreated controls (P < 0.05). The number of KLE cells was increased 2.6-fold by EGF (100 ng/ml), 2.3-fold by IGF-I (100 ng/ml), 2.1-fold by IGF-II (100 ng/ml), and 2.0-fold by insulin (1000 ng/ml) when compared to untreated controls (P < 0.05). Similar results were obtained when DNA content was measured. PDGF failed to stimulate any mitogenic response in either cell line at all concentrations tested (0.1-100 ng/ml). These findings suggest that EGF, IGF-I, IGF-II, and insulin may play a regulatory role in the proliferation of endometrial adenocarcinoma.
Pearl
M L
ML
Department of Obstetrics and Gynecology, University of Michigan Medical Center, Ann Arbor 48109-0718.
Talavera
F
F
Gretz
H F
HF
Roberts
J A
JA
Menon
K M
KM
D000230:Adenocarcinoma / Q000473:pathology*; D000704:Analysis of Variance; D004273:DNA, Neoplasm / Q000032:analysis; D016889:Endometrial Neoplasms / Q000473:pathology*; D004815:Epidermal Growth Factor / Q000502:physiology; D005260:Female; D006133:Growth Substances / Q000502:physiology*; D006801:Humans; D008938:Mitosis / Q000502:physiology*; D010982:Platelet-Derived Growth Factor / Q000502:physiology; D013002:Somatomedins / Q000502:physiology; D013936:Thymidine; D013997:Time Factors; D014407:Tumor Cells, Cultured
D004273:DNA, Neoplasm; D006133:Growth Substances; D010982:Platelet-Derived Growth Factor; D013002:Somatomedins; D004815:Epidermal Growth Factor; D013936:Thymidine